This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Technology Names: Palantir Technologies (PLTR) and Ichor Holdings (ICHR)

Tipranks - Wed May 6, 12:44AM CDT

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Palantir Technologies (PLTR) and Ichor Holdings (ICHR).

Claim 55% Off TipRanks

Palantir Technologies (PLTR)

In a report released today, Brent Thill from Jefferies maintained a Sell rating on Palantir Technologies, with a price target of $70.00. The company’s shares closed last Monday at $146.03.

According to TipRanks.com, Thill is a 4-star analyst with an average return of 2.5% and a 50.6% success rate. Thill covers the Technology sector, focusing on stocks such as International Business Machines, Procore Technologies, and Progress Software. ;'>

Palantir Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $184.63, implying a 25.0% upside from current levels. In a report issued on April 28, RBC Capital also maintained a Sell rating on the stock with a $90.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Ichor Holdings (ICHR)

TD Cowen analyst Krish Sankar maintained a Buy rating on Ichor Holdings today and set a price target of $80.00. The company’s shares closed last Monday at $69.72.

According to TipRanks.com, Sankar is a top 25 analyst with an average return of 51.1% and a 69.8% success rate. Sankar covers the Technology sector, focusing on stocks such as Ultra Clean Holdings, ARM Holdings PLC ADR, and GlobalFoundries Inc. ;'>

Ichor Holdings has an analyst consensus of Strong Buy, with a price target consensus of $61.29, representing a -10.0% downside. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $71.00 price target.

Read More on PLTR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.